| Particulars (Rupees in Crores.) | Jun-2025 | Mar-2025 | Dec-2024 | Sept-2024 | Jun-2024 |
|---|---|---|---|---|---|
Gross Sales | 1,024.03 | 1,055.55 | 1,010.41 | 1,033.09 | 1,019.11 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,024.03 | 1,055.55 | 1,010.41 | 1,033.09 | 1,019.11 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 26.73 | 25.76 | 19.34 | 17.17 | 6.55 |
Total Income | 1,050.76 | 1,081.31 | 1,029.75 | 1,050.26 | 1,025.66 |
Total Expenditure | 895.06 | 961.63 | 889.05 | 911.9 | 891.1 |
PBIDT | 155.7 | 119.68 | 140.71 | 138.35 | 134.56 |
Interest | 23.14 | 4.54 | 5.13 | 11.9 | 13.02 |
PBDT | 132.57 | 115.13 | 135.57 | 126.45 | 121.54 |
Depreciation | 36.92 | 40 | 44.52 | 34.87 | 34.06 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 24.44 | 20.41 | 19.8 | 21.95 | 18.76 |
Deferred Tax | 6.52 | -94.88 | 4.95 | 2.99 | 7.52 |
Reported Profit After Tax | 64.69 | 149.61 | 66.31 | 66.65 | 61.21 |
Minority Interest After NP | 1.21 | 1.99 | 1.13 | 1.45 | 1.04 |
Net Profit after Minority Interest | 63.48 | 147.62 | 65.18 | 65.21 | 60.17 |
Extra-ordinary Items | 0 | 5.98 | 3.48 | 2.69 | 0 |
Adjusted Profit After Extra-ordinary item | 63.48 | 141.64 | 61.7 | 62.52 | 60.17 |
EPS (Unit Curr.) | 4.15 | 9.64 | 4.26 | 4.37 | 4.21 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 30.62 | 30.62 | 30.62 | 30.62 | 28.61 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 15.2 | 11.33 | 13.92 | 13.39 | 13.2 |
PBDTM(%) | 12.94 | 10.9 | 13.41 | 12.23 | 11.92 |
PATM(%) | 6.31 | 14.17 | 6.56 | 6.45 | 6 |
The organisation is the largest CDMO serving the Indian pharmaceutical industry, with a proven track record and a broad clientele.
The IPO comprised a fresh issue of shares worth ₹680 crore and an offer-for-sale (OFS) of 1.73 crore shares, aggregating ₹1,177 crore.
The IPO consists of a fresh issue of ₹680 crore and an offer for sale (OFS) of up to 1.73 crore shares at a face value of ₹2 each.
On Monday, the business said that it had received ₹829 crore from anchor investors ahead of the public share sale subscription period.
The IPO includes a new issue of 1 Crore shares worth ₹680.00 Crore and an offer for sale of 1.73 Crore shares worth ₹1,176.74 Crore.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
